RALEIGH, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly ...
PRA Health Sciences, Inc. PRAH recently launched Symphony Health’s national market measurement tool, known as Metys, in an effort to enhance its position and capabilities in the data and analytics ...
BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its ...
The first of its kind, Metys delivers accurate, reliable data quickly through a single access point RALEIGH, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today ...
SMi reports: Metys Pharmaceuticals, Ensysce Biosciences & AstraZeneca will be speaking and presenting at the 19th Annual Pain Therapeutics conference in London, this May. Pain Therapeutics 2019 will ...
Acquisition of Metys broadens Novaremed’s pipeline focused on novel, non-opioid development candidates for chronic pain indications with the addition of two complementary development projects ...
* PRA HEALTH SCIENCES - SYMPHONY HEALTH TO MAKE A 30-DAY LICENSE OF METYS COVID-19 MODULE AVAILABLE TO U.S. LIFE SCIENCE INDUSTRY AT NO CHARGE Source text for Eikon: Further company coverage: ...
Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results